Company Overview
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Company Information
- CEO
- Matthew P. Blischak
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
Contact Information
- Address
- 200 Inner Belt Road
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 20.87M market capitalization
- Trading Volume: 187 shares traded today
- Price Range: 52-week range of $10.15 - $15.85
- Exchange: Listed on Other OTC
Financial Metrics
Market Analysis for Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc. (FNCH) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 20.87M, the company represents a significant player in its market. The stock is currently trading at $13.00 with a positivedaily change of 6.12%.
The company's 1 employee base and presence on the Other OTCexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -1.48, beta of 1.18, and 52-week price range from $10.15 to $15.85when evaluating investment opportunities.
Why Invest in Finch Therapeutics Group, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (Other OTC)
- • Experienced leadership under Matthew P. Blischak
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.